For a drug to be prescribed to a patient, it must first be rigorously tested for efficacy and safety and subsequently be approved by relevant authoritative bodies, such as the European Medicines Agency (EMA). However, the current framework of drug development is heavily ‘drug-focused’ rather than ‘patient-focused’. This means that the end users of the drug, the patients, are not generally placed at the centre of the drug development paradigm. Medical treatment is insufficiently personalised, especially when fighting cancer. In other words, achieving regulatory approval is seen as the ultimate goal, eclipsing somewhat the use of a drug in its real-world setting. This is not helped by the lack of regulatory demands or incentives for gathering such real world data. Restrictions: ©The material may not be edited and must be shown entirely.

DG EPRS

healthcare safety (T)

European Medicines Agency

EPRS publication (T)

EPRS - Tailoring medicine to patient needs

https://api.multimedia.europarl.europa.eu/documents/20125/4347539/EP118055Chapters%5BSD-EN%5D.srt